Association of cyclophosphamide pharmacokinetics to polymorphic cytochrome P450 2C19

Pharmacogenomics Journal

Volumn 5, Issue 6, 2005, Pages 365-373

  Timm, R ^a   Kaiser, R ^b   Lotsch J ^c   Heider, U ^d   Sezer, O ^d   Weisz, K ^a   Montemurro, M ^a   Roots, I ^d   Cascorbi, I ^a,e  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

CHOP; Cyclophosphamide; CYP2C19; Cytochrome P450; Drug metabolism; Pharmacogenetics

Indexed keywords

4 OXOCYCLOPHOSPHAMIDE; CARBOXYPHOSPHAMIDE; CYCLOPHOSPHAMIDE; CYTOCHROME P450; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A5; DECHLOROMETHYLCYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG METABOLITE; ETOPOSIDE; GLUTATHIONE TRANSFERASE A1; IFOSFAMIDE; PREDNISONE; TRANSFERASE; UNCLASSIFIED DRUG; VINCRISTINE; CYP2C19 PROTEIN, HUMAN; MIXED FUNCTION OXIDASE; UNSPECIFIC MONOOXYGENASE;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; BREAST CANCER; CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG URINE LEVEL; ENZYME INDUCTION; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PHARMACOGENOMICS; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; POPULATION MODEL; PRIORITY JOURNAL; STATISTICAL MODEL; GENE FREQUENCY; GENETICS; MIDDLE AGED; URINE;

ADULT; AGED; ARYL HYDROCARBON HYDROXYLASES; CYCLOPHOSPHAMIDE; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES;

EID: 32644465703     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500330     Document Type: Article

References (38)

1. Hanel M, Kroger N, Sonnenberg S, Bornhauser M, Kruger W, Kroschinsky F et al. Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma. Ann Hematol 2002; 81: 96-102.
2. Tam CS, Wolf MM, Januszewicz EH, Prince HM, Westerman D, Seymour JF. Fludarabine and cyclophosphamide using an attenuated dose schedule is a highly effective regimen for patients with indolent lymphoid malignancies. Cancer 2004; 100: 2181-2189.
3. Rodenhuis S. High-dose chemotherapy in breast cancer - interpretation of the randomized trials. Anticancer Drugs 2001; 12: 85-88.
4. Ben Ari ET. Dual purpose: Some cancer therapies used to treat autoimmune diseases. J Natl Cancer Inst 2004; 96: 577-579.
5. Pendse S, Ginsburg E, Singh AK. Strategies for preservation of ovarian and testicular function after immunosuppression. Am J Kidney Dis 2004; 43: 772-781.
6. Martoni A, Panetta A, Angelelli B, Melotti B, Pannuti F. A phase II study of carboplatin and cyclophosphamide in advanced ovarian carcinoma. J Chemother 1993; 5: 47-51.
7. Fraiser LH, Kanekal S, Kehrer JP. Cyclophosphamide toxicity. Characterising and avoiding the problem. Drugs 1991; 42: 781-795.
8. Buckner CD, Rudolph RH, Fefer A, Clift RA, Epstein RB, Funk DD et al. High-dose cyclophosphamide therapy for malignant disease: Toxicity, tumor response, and the effect of stored autologous marrow. Cancer 1972; 29: 357-365.
9. Newell DR, Gore ME. Toxicity of alkylating agents: Clinical characteristics and pharmacokinetic determinants. In: Powis G, Hacker MP (eds). The Toxicity of Anticancer Drugs. Pergamon: New York, 1991, pp 44-62.
10. Langford CA. Complications of cyclophosphamide therapy. Eur Arch Otorhinolaryngol 1997, 254: 65-72.
11. Brock N, Stekar J, Pohl J, Niemeyer U, Scheffler G. Acrolein, the causative factor of urotoxic side-effects of cyclophosphamide, ifosfamide, trofosfamide and sufosfamide. Arzneimittelforschung 1979; 29: 659-661.
12. Chang TK, Yu L, Goldstein JA, Waxman DJ. Identification of the polymorphically expressed CYP2C19 and the wild type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation. Pharmacogenetics 1997; 7: 211-221.
13. Griskevicius L, Yasar U, Sandberg M, Hidestrand M, Eliasson E, Tybring G et al. Bioactivation of cyclophosphamide: The role of polymorphic CYP2C enzymes. Eur J Clin Pharmacol 2003; 59: 103-109.
14. Ren S, Yang JS, Kalhorn TF, Slattery JT. Oxidation of cyclophosphamide to 4-hydroxycyclophosphamide and deschloroethylcyclophosphamide in human liver microsomes. Cancer Res 1997; 57: 4229-4235.
15. Chang TK, Weber GF, Crespi CL, Waxman DJ. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res 1993; 53: 5629-5637.
16. Roy P, Yu LJ, Crespi CL, Waxman DJ. Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos 1999; 27: 655-666.
17. Xie HJ, Yasar U, Lundgren S, Griskevicius L, Terelius Y, Hassan M et al. Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation. Pharmacogenomics J 2003; 3: 53-61.
18. Finta C, Zaphiropoulos PG. The human cytochrome P450 3A locus. Gene evolution by capture of downstream exons. Gene 2000; 260: 13-23.
19. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27: 383-391.
20. Hustert E, Haberl M, Burk O, Wolbold R, He YQ, Klein K et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001; 11: 773-779.
21. Dirven HA, van Ommen B, van Bladeren PJ. Involvement of human glutathione S-transferase isoenzymes in the conjugation of cyclophosphamide metabolites with glutathione. Cancer Res 1994; 54: 6215-6220.
22. Bohnenstengel F, Hofmann U, Eichelbaum M, Kroemer HK. Characterization of the cytochrome P450 involved in side-chain oxidation of cyclophosphamide in humans. Eur J Clin Pharmacol 1996; 51: 297-301.
23. Huang Z, Roy P, Waxman DJ. Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide. Biochem Pharmacol 2000; 59: 961-972.
24. Sladek NE. Metabolism of oxazaphosphorines. Pharmacol Ther 1988; 37: 301-355.
25. Dockham PA, Lee MO, Sladek NE. Identification of human liver aldehyde dehydrogenases that catalyze the oxidation of aldophosphamide and retinaldehyde. Biochem Pharmacol 1992; 43: 2453-2469.
26. Agarwal DP, von Eitzen U, Meier-Tackmann D, Goedde HW. Metabolism of cyclophosphamide by aldehyde dehydrogenases. Adv Exp Med Biol 1995; 372: 115-122.
27. Lartigue-Mattei C, Chabard JL, Touzet C, Chollet P, Plagne R, Petit J et al. Pharmacokinetics of cyclophosphamide administered alone or in combination with vindesin or cisplatin in 5 patients with bronchial adenocarcinoma. Biomed Pharmacother 1988; 42: 555-559.
28. Gervot L, Rochat B, Gautier JC, Bohnenstengel F, Kroemer H, de B et al. Human CYP2B6: Expression, inducibility and catalytic activities. Pharmacogenetics 1999; 9: 295-306.
29. Martin H, Sarsat JP, de W, I, Housset C, Balladur P, Beaune P et al. Induction of cytochrome P450 2B6 and 3A4 expression by phenobarbital and cyclophosphamide in cultured human liver slices. Pharm Res 2003; 20: 557-568.
30. Wang H, Faucette S, Sueyoshi T, Moore R, Ferguson S, Negishi M et al. A novel distal enhancer module regulated by pregnane X receptor/ constitutive androstane receptor is essential for the maximal induction of CYP2B6 gene expression. J Biol Chem 2003; 278: 14146-14152.
31. Takada K, Arefayene M, Desta Z, Yarboro CH, Boumpas DT, Balow JE et al. Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis. Arthritis Rheum 2004; 50: 2202-2210.
32. Kirchheiner J, Klein C, Meineke I, Sasse J, Zanger UM, Murdter TE et al. Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics 2003; 13: 619-626.
33. Petros W, Broadwater G, Colvin M, Marks J. Association of CYP3A5 genotype with cyclophosphamide pharmacokinetics and overall survival in patients with breast cancer. Proc Am Assoc Cancer Res 2004, p 45 (Abstract).
34. Niemi M, Cascorbi I, Timm R, Kroemer HK, Neuvonen PJ, Kivisto KT. Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes. Clin Pharmacol Ther 2002; 72: 326-332.
35. Lang T, Klein K, Fischer J, Nussler AK, Neuhaus P, Hofmann U et al. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 2001; 11: 399-415.
36. King BP, Leathart JB, Mutch E, Williams FM, Daly AK. CYP3A5 phenotype-genotype correlations in a British population. Br J Clin Pharmacol 2003; 55: 625-629.
37. Coles BF, Morel F, Rauch C, Huber WW, Yang M, Teitel CH et al. Effect of polymorphism in the human glutathione S-transferase A1 promoter on hepatic GSTA1 and GSTA2 expression. Pharmacogenetics 2001; 11: 663-669.
38. Busse D, Busch FW, Bohnenstengel F, Eichelbaum M, Fischer P, Opalinska J et al. Dose escalation of cyclophosphamide in patients with breast cancer: Consequences for pharmacokinetics and metabolism. J Clin Oncol 1997; 15: 1885-1896.